PA8685101A1 - Formas cristalinas de 4-[2,4-dicloro-5-metoxifenil)amino]-6-metoxi-7-[3-(4-metil-1-piperazinil) propoxi]-3-quinolincarbonitrilo y metodos de preparacion de las mismas - Google Patents
Formas cristalinas de 4-[2,4-dicloro-5-metoxifenil)amino]-6-metoxi-7-[3-(4-metil-1-piperazinil) propoxi]-3-quinolincarbonitrilo y metodos de preparacion de las mismasInfo
- Publication number
- PA8685101A1 PA8685101A1 PA20068685101A PA8685101A PA8685101A1 PA 8685101 A1 PA8685101 A1 PA 8685101A1 PA 20068685101 A PA20068685101 A PA 20068685101A PA 8685101 A PA8685101 A PA 8685101A PA 8685101 A1 PA8685101 A1 PA 8685101A1
- Authority
- PA
- Panama
- Prior art keywords
- chinolincarbonitrile
- metoxifenil
- propoxi
- metoxi
- dicloro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
ESTA INVENCIÓN ESTÁ DIRIGIDA A UN 4-[2,4-DICLORO-5-METOXIFENIL)AMINO]-6-METOXI-7-[3-(4-METIL-1-PIPERAZINIL)PROPOXI]-3-QUINOLINCARBONITRILO MONOHIDRATO CRISTALINO QUE POSEE UN PATRÓN DE DIFRACCIÓN DE RAYOS X EN DONDE LOS ÁNGULOS 20 (°) DE PICOS SIGNIFICATIVOS SE ENCUENTRAN A APROXIMADAMENTE: 9,19, 11,48, 14,32, 19,16, 19,45, 20,46, 21,29, 22,33, 23,96, 24,95, 25,29, 25,84, 26,55, 27,61, Y 29,51 Y UNA TEMPERATURA DE TRANSICIÓN DE APROXIMADAMENTE 109°C A APROXIMADAMENTE 115°C.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69638105P | 2005-07-01 | 2005-07-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
PA8685101A1 true PA8685101A1 (es) | 2007-01-17 |
Family
ID=37103295
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PA20068685101A PA8685101A1 (es) | 2005-07-01 | 2006-06-30 | Formas cristalinas de 4-[2,4-dicloro-5-metoxifenil)amino]-6-metoxi-7-[3-(4-metil-1-piperazinil) propoxi]-3-quinolincarbonitrilo y metodos de preparacion de las mismas |
Country Status (25)
Country | Link |
---|---|
US (2) | US7767678B2 (es) |
EP (1) | EP1902029B2 (es) |
JP (1) | JP2009500332A (es) |
KR (1) | KR20080028386A (es) |
CN (1) | CN101248047A (es) |
AR (1) | AR054505A1 (es) |
AU (1) | AU2006266045A1 (es) |
BR (1) | BRPI0613574A2 (es) |
CA (1) | CA2613053C (es) |
CR (1) | CR9596A (es) |
DK (1) | DK1902029T4 (es) |
EC (1) | ECSP078063A (es) |
ES (1) | ES2449197T5 (es) |
GT (1) | GT200600282A (es) |
HK (1) | HK1114614A1 (es) |
IL (1) | IL188483A0 (es) |
MX (1) | MX2008000384A (es) |
NO (1) | NO20080051L (es) |
PA (1) | PA8685101A1 (es) |
PE (1) | PE20070190A1 (es) |
PL (1) | PL1902029T5 (es) |
PT (1) | PT1902029E (es) |
RU (1) | RU2007148072A (es) |
TW (1) | TW200740797A (es) |
WO (1) | WO2007005462A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102470109A (zh) * | 2009-07-02 | 2012-05-23 | 惠氏有限责任公司 | 3-氰基喹啉片剂制剂及其应用 |
WO2013187967A1 (en) | 2012-06-15 | 2013-12-19 | Institute For Cancer Research D/B/A The Research Institute Of Fox Case Cancer Center ("Fox Chase Cancer Center") | Sensitization of cancer cells to dna damage by inhibiting kinases essential for dna damage checkpoint control |
CN104447541A (zh) * | 2013-09-16 | 2015-03-25 | 天津市汉康医药生物技术有限公司 | 博舒替尼化合物 |
IN2014CH00840A (es) * | 2014-02-20 | 2015-09-18 | Apotex Inc | |
WO2015149727A1 (en) | 2014-04-02 | 2015-10-08 | Zentiva, K.S. | Novel solid phases of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1 -piperazinyl)propoxy]-3-quinolinecarbonitrile |
WO2016034150A1 (zh) * | 2014-09-04 | 2016-03-10 | 正大天晴药业集团股份有限公司 | 博舒替尼及其结晶的制备方法 |
CN105384686B (zh) * | 2014-09-04 | 2019-07-26 | 连云港润众制药有限公司 | 一种博舒替尼结晶方法 |
WO2017029584A1 (en) * | 2015-08-19 | 2017-02-23 | Sun Pharmaceutical Industries Limited | Amorphous form of bosutinib |
WO2017134679A1 (en) * | 2016-02-03 | 2017-08-10 | Msn Laboratories Private Limited | Novel crystalline polymorphs of 4-[(2.4-dichioro-5-methoxvphenvl)aniinol- 6-methoxv-7-13-(4-methyl-l-piperazinvl)propoxvl-3-quinolinecarbonitrile and process for preparation thereof |
WO2017145089A1 (en) * | 2016-02-23 | 2017-08-31 | Sun Pharmaceutical Industries Limited | Crystalline form x of bosutinib |
CN105646345A (zh) * | 2016-03-16 | 2016-06-08 | 浙江海正药业股份有限公司 | 博舒替尼的新晶型及其制备方法 |
CN106187886B (zh) * | 2016-07-06 | 2019-04-16 | 山东创新药物研发有限公司 | 一种制备高纯度伯舒替尼一水合物的方法 |
JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
CN110317168A (zh) * | 2018-03-30 | 2019-10-11 | 正大天晴药业集团股份有限公司 | 一种博舒替尼的纯化方法 |
TW202016110A (zh) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Jak激酶家族之小分子抑制劑 |
EP3953450A1 (en) | 2019-04-09 | 2022-02-16 | Massachusetts Institute Of Technology | A micro physiological model for neuronal and muscular diseases and disorders |
CN112321505B (zh) * | 2019-10-25 | 2022-08-23 | 杭州中美华东制药有限公司 | 一种伯舒替尼晶型及其制备方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
US6432979B1 (en) * | 1999-08-12 | 2002-08-13 | American Cyanamid Company | Method of treating or inhibiting colonic polyps and colorectal cancer |
UA77200C2 (en) * | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
TWI275390B (en) * | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
TW200423938A (en) * | 2003-02-21 | 2004-11-16 | Wyeth Corp | 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury |
MXPA06001590A (es) * | 2003-08-19 | 2006-05-19 | Wyeth Corp | Proceso para la preparacion de 4-amino-3-quinolincarbonitrilos. |
WO2005065074A2 (en) * | 2003-09-09 | 2005-07-21 | Temple University Of The Commonwealth System Of Higher Education | Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors |
AU2003291245A1 (en) * | 2003-11-06 | 2004-06-06 | Wyeth | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml) |
US7910211B2 (en) * | 2005-06-20 | 2011-03-22 | E.I. Du Pont De Nemours And Company | Process for the production of multi-layer coatings |
KR20080027275A (ko) | 2005-06-24 | 2008-03-26 | 와이어쓰 | 암의 치료를 위한 4-아닐리노-3-퀴놀린카르보니트릴 |
US8520232B2 (en) * | 2006-03-31 | 2013-08-27 | Konica Minolta Laboratory U.S.A., Inc. | Print job analyzing method and apparatus with print device recommendation functions |
-
2006
- 2006-06-28 RU RU2007148072/04A patent/RU2007148072A/ru not_active Application Discontinuation
- 2006-06-28 WO PCT/US2006/025160 patent/WO2007005462A1/en active Application Filing
- 2006-06-28 AU AU2006266045A patent/AU2006266045A1/en not_active Abandoned
- 2006-06-28 MX MX2008000384A patent/MX2008000384A/es unknown
- 2006-06-28 ES ES06774184T patent/ES2449197T5/es active Active
- 2006-06-28 CA CA2613053A patent/CA2613053C/en active Active
- 2006-06-28 DK DK06774184.3T patent/DK1902029T4/da active
- 2006-06-28 EP EP06774184.3A patent/EP1902029B2/en active Active
- 2006-06-28 CN CNA2006800311714A patent/CN101248047A/zh not_active Withdrawn
- 2006-06-28 KR KR1020077030989A patent/KR20080028386A/ko not_active Application Discontinuation
- 2006-06-28 JP JP2008519519A patent/JP2009500332A/ja active Pending
- 2006-06-28 PL PL06774184.3T patent/PL1902029T5/pl unknown
- 2006-06-28 PT PT67741843T patent/PT1902029E/pt unknown
- 2006-06-28 BR BRPI0613574A patent/BRPI0613574A2/pt not_active IP Right Cessation
- 2006-06-29 GT GT200600282A patent/GT200600282A/es unknown
- 2006-06-29 AR ARP060102806A patent/AR054505A1/es unknown
- 2006-06-29 US US11/478,216 patent/US7767678B2/en active Active
- 2006-06-30 TW TW095123896A patent/TW200740797A/zh unknown
- 2006-06-30 PA PA20068685101A patent/PA8685101A1/es unknown
- 2006-07-03 PE PE2006000770A patent/PE20070190A1/es not_active Application Discontinuation
-
2007
- 2007-12-17 CR CR9596A patent/CR9596A/es not_active Application Discontinuation
- 2007-12-27 IL IL188483A patent/IL188483A0/en unknown
- 2007-12-28 EC EC2007008063A patent/ECSP078063A/es unknown
-
2008
- 2008-01-04 NO NO20080051A patent/NO20080051L/no not_active Application Discontinuation
- 2008-09-12 HK HK08110155.2A patent/HK1114614A1/xx active IP Right Maintenance
-
2010
- 2010-06-22 US US12/820,306 patent/US8445496B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
NO20080051L (no) | 2008-01-29 |
ES2449197T3 (es) | 2014-03-18 |
US20100324066A1 (en) | 2010-12-23 |
IL188483A0 (en) | 2008-04-13 |
JP2009500332A (ja) | 2009-01-08 |
CR9596A (es) | 2008-03-06 |
DK1902029T4 (da) | 2022-02-28 |
US20070015767A1 (en) | 2007-01-18 |
WO2007005462A1 (en) | 2007-01-11 |
AR054505A1 (es) | 2007-06-27 |
US8445496B2 (en) | 2013-05-21 |
PL1902029T5 (pl) | 2022-08-29 |
CA2613053A1 (en) | 2007-01-11 |
EP1902029B1 (en) | 2014-01-08 |
EP1902029B2 (en) | 2022-02-16 |
MX2008000384A (es) | 2008-03-07 |
PL1902029T3 (pl) | 2014-08-29 |
US7767678B2 (en) | 2010-08-03 |
KR20080028386A (ko) | 2008-03-31 |
AU2006266045A1 (en) | 2007-01-11 |
CA2613053C (en) | 2015-11-24 |
DK1902029T3 (en) | 2014-02-17 |
ECSP078063A (es) | 2008-01-23 |
RU2007148072A (ru) | 2009-08-10 |
HK1114614A1 (en) | 2008-11-07 |
GT200600282A (es) | 2007-02-14 |
PT1902029E (pt) | 2014-03-05 |
BRPI0613574A2 (pt) | 2016-11-16 |
PE20070190A1 (es) | 2007-03-20 |
CN101248047A (zh) | 2008-08-20 |
TW200740797A (en) | 2007-11-01 |
ES2449197T5 (es) | 2022-04-28 |
EP1902029A1 (en) | 2008-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PA8685101A1 (es) | Formas cristalinas de 4-[2,4-dicloro-5-metoxifenil)amino]-6-metoxi-7-[3-(4-metil-1-piperazinil) propoxi]-3-quinolincarbonitrilo y metodos de preparacion de las mismas | |
DE602006020327D1 (de) | 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-aminder-hemmer zur behandlung thromboembolischer erkrankungen | |
NO20054264D0 (no) | Ikke-Nukleoside Revers Transkriptase-Inhibitorer I for behandling av HIV-medierte sydommer | |
CR9869A (es) | Compuestos activos en ppar | |
FR15C0028I2 (fr) | Fabrication de tiacumicine | |
DK1562589T3 (da) | Diaminotriazoler der er nyttige som inhibitorer af proteinkinaser | |
ECSP066467A (es) | Formas Polimórficas de 3-(4-amino-1-Oxo-1-3 DIhidroisoindol-2-IL)-Piperidin-2,6-Diona | |
NO20044617L (no) | Substituerte benzazoler og anvendelse derav som RAF kinaseinbibitorer | |
DE602004008227D1 (de) | Inhibitoren dernicht-nukleosid-inhibitoren der reversen transkriptase | |
NO20040933L (no) | Nye gamma-sekretaseinhibitorer. | |
NO20053356L (no) | Aminindazolderivater og anvendelse derav som kinaseinhibitorer. | |
DK2308507T3 (da) | Fremgangsmåder til behandling af præeklampsi | |
NO20053215D0 (no) | Pyrazolderivater med anvendelse som COX-1-inhibitorer. | |
NO20033618D0 (no) | Ftalayinon-piperidino-derivater som PDE-4-inhibitorer | |
SV2008002542A (es) | Formas solidas cristalinas de tigeciclina y metodos para preparar los mismos ref. 01142.0379-00267 (am101946sv) | |
DK1496912T3 (da) | Kombination af brimonidin og timolol til topisk, ophthalmisk anvendelse | |
DE602005017604D1 (de) | Inhibitoren der nicht-nukleosid-inhibitoren der reversen transkriptase | |
CR11416A (es) | Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos | |
LU92326I2 (fr) | Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS) | |
CL2007002384A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis. | |
DK1801108T3 (da) | Morpholinforbindelser til behandling af inflammationer. | |
CL2007002380A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica. | |
DK1600441T3 (da) | Krystallinsk form af elrcanidipinhydrochlorid til anvendelse som et antihypertensivt middel | |
NO20043842L (no) | Nye krystallformer av atorvastatinhemikalsium og fremgangsmater for fremstilling derav, savel som nye fremgangsmater for fremstilling av atorvastatinhemikalsiumform I, VIII og IX | |
NO20055450D0 (no) | Kombinasjon av et analeptisk modafinili og en antidepressiv forbindelse for behandling av depresjon |